BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10543734)

  • 1. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
    Denning DW; Warn P
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.
    Wallace TL; Paetznick V; Cossum PA; Lopez-Berestein G; Rex JH; Anaissie E
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2238-43. PubMed ID: 9333054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
    Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
    Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
    Clemons KV; Schwartz JA; Stevens DA
    Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.
    Oakley KL; Moore CB; Denning DW
    Antimicrob Agents Chemother; 1999 May; 43(5):1264-6. PubMed ID: 10223948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
    Clemons KV; Stevens DA
    J Antimicrob Chemother; 1992 Sep; 30(3):353-63. PubMed ID: 1452501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
    J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and experimental invasive aspergillosis.
    Sirivoranankul C; Martinez M; Chen V; Clemons KV; Stevens DA
    Med Mycol; 2014 Nov; 52(8):847-52. PubMed ID: 25231772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.
    Warn PA; Morrissey J; Moore CB; Denning DW
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2664-71. PubMed ID: 10991841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
    Al-Nakeeb Z; Petraitis V; Goodwin J; Petraitiene R; Walsh TJ; Hope WW
    Antimicrob Agents Chemother; 2015 May; 59(5):2735-45. PubMed ID: 25712363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
    Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA
    J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.
    Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ
    J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis.
    Mylonakis E; Chalevelakis G; Saroglou G; Danias P; Argyropoulou AD; Paniara O; Raptis SA
    Mayo Clin Proc; 1997 Nov; 72(11):1022-7. PubMed ID: 9374975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
    Warn PA; Sharp A; Morrissey G; Denning DW
    Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.